# Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery

> **NCT00888940** · PHASE2 · COMPLETED · sponsor: **Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 243 (actual)

## Conditions studied

- Bloodloss
- Surgical Procedures, Operative

## Interventions

- **DRUG:** Ecallantide
- **DRUG:** Cyklokapron(R)

## Key facts

- **NCT ID:** NCT00888940
- **Lead sponsor:** Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2009-12
- **Final completion:** 2010-01
- **Target enrollment:** 243 (ACTUAL)
- **Last updated:** 2015-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00888940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00888940, "Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00888940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*